Combination Therapy for Androgen Deficiency
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current testosterone therapies for male hypogonadism often suppress endogenous testosterone production and spermatogenesis due to feedback inhibition, leading to adverse effects on fertility and muscle mass, necessitating a therapy that maintains fertility while elevating testosterone levels.
Innovation Solution
A combination therapy involving co-administration of an antiestrogen, such as trans-clomiphene, with an androgen or an aromatase inhibitor, like anastrozole, letrozole, or exemestane, to elevate testosterone levels and maintain fertility parameters, particularly in males with secondary hypogonadism and high body mass index.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If exogenous testosterone is administered to treat hypogonadism, then testosterone levels are elevated, but endogenous testosterone production and spermatogenesis are suppressed due to feedback inhibition
Solution Approach 1:
The patent segments the hormonal regulation system by introducing an antiestrogen agent that specifically blocks estrogen feedback to the pituitary gland, while allowing other hormonal pathways to remain intact. This selective blockade maintains LH secretion and endogenous testosterone production despite exogenous testosterone administration, thereby preserving spermatogenesis.
Solution Approach 2:
The antiestrogen agent acts as an intermediary substance that interferes with the feedback loop between estrogen and the pituitary gland. By blocking estrogen receptors in the pituitary, it prevents the suppressive feedback signal from reaching the gonadotropin-secreting cells, thus maintaining LH and FSH secretion necessary for spermatogenesis while allowing testosterone levels to be elevated.
2Object-affected harmful factors
If traditional testosterone replacement therapy is used, then symptoms of hypogonadism are alleviated, but muscle mass and fertility are adversely affected
Solution Approach 1:
The patent employs a dynamic combination therapy approach where the antiestrogen agent is administered concurrently with exogenous testosterone. This dynamic regimen allows the system to adapt by maintaining elevated LH levels through feedback blockade, thereby sustaining endogenous testosterone production that supports muscle mass, while simultaneously treating hypogonadism symptoms.
Solution Approach 2:
The therapy uses a composite pharmacological approach combining two distinct agents: exogenous testosterone to elevate overall testosterone levels and an antiestrogen agent to specifically block feedback inhibition. This composite therapy achieves synergistic effects, treating hypogonadism symptoms while preserving the anabolic effects on muscle mass and fertility.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The combination therapy effectively maintains or increases testosterone levels, preserves fertility by sustaining pituitary gonadotropin secretion, and reduces estrogen conversion, thereby alleviating symptoms of hypogonadism without the adverse effects on sperm count and muscle mass associated with traditional therapies.
Implementation Method 1
exogenous administration of androgens (e.g. testosterone) has the effect of suppressing secretion of pituitary gonadotropins and therefore can significantly reduce sperm count... In particular, exogenous administration of testosterone leads to an inhibition of endogenous testosterone release through feedback inhibition of pituitary LH
Implementation Method 2
an aromatase inhibitor in order to elevate testosterone levels... co-administration of an antiestrogen with an aromatase inhibitor
Implementation Method 3
LH, in turn, regulates the production and secretion of testosterone in the Leydig cells of the testes
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention relates to a combination therapy for elevating testosterone levels in male mammals in which an antiestrogen or pharmaceutically acceptable salt thereof is co-administered to the mammal with an additional therapeutic agent selected from an androgen and an aromatase inhibitor. The invention is also directed to a combination therapy for treating males with hypogonadism and disorders related thereto, including reduction of muscle mass. limitation of body performance capacity, reduction of bone density, reduction of libido, reduction of potency, reduction of benign prostatic hyperplasia and infertility.